Prolung Inc   (FRES)
Other Ticker:  
Price: $4.4899 $0.10 2.276%
Day's High: $4.4899 Week Perf: -2.12 %
Day's Low: $ 4.24 30 Day Perf:
Volume (M): 3 52 Wk High: $ 5.49
Volume (M$): $ 15 52 Wk Avg: $4.54
Open: $4.31 52 Wk Low: $4.00

 Market Capitalization (Millions $) 21
 Shares Outstanding (Millions) 5
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -3
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Prolung Inc

   Company Address: 350 W. 800 N. Salt Lake City 84103 UT
   Company Phone Number: 736?0729   Stock Exchange / Ticker: FRES
   FRES is expected to report next financial results on August 14, 2023.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Prolung Inc

The arising entity from the Laboratory Analytical Instruments industry the FRES reported the first quarter of 2023 earnings season, results

As a cautious investor, it is important to take heed of the laboratory analytical instruments sector's first quarter earnings report for 2023. The operating deficit of $-0.568664 million for the period of January to March 2023 is a cause for concern, especially given that the company has not released any top-line figures thus far. This represents an increase compared to the first quarter of 2022, where the operating deficit was $-1.430521 million.
It is important to note that the operating deficit is a vital indicator for the course of the company. As corporations like FRES continue to develop revenue streams, it is crucial for them to operate cost-effectively to attain another level. The encouraging news is that the diminishing returns have decreased to $-0.809 million, from $-1.761 million in the first quarter of 2022, which may benefit the organization on its course to be a doyen in the industry.

Thermogenesis Holdings Inc

A negligible Decline in revenue at Thermogenesis Holdings Inc in the most recent fiscal period

As a journalist, it is my job to analyze the financial results of Thermogenesis Holdings Inc, which recorded a cumulative net loss of $-15 million during the 12 months ending in the first quarter of 2023. This negative return on investment (ROI) of -179.28% is concerning for the company and its investors.
Looking at the Healthcare sector, it is noted that 751 other companies had a higher ROI, highlighting that Thermogenesis Holdings Inc is not performing as well as its peers. However, there is some optimism in the fact that the overall ranking for ROI has progressed in the Mar 31 2023 quarter, so far to 3605 from the total ROI ranking in the fourth quarter of 2022 at 4799. This shows that the company may be taking some steps to improve its financial performanceThe lower revenue in the financial period ending March 31 2023 is certainly a factor that has led to the losses recorded. Revenue sunk by -3.417% to $2.57 million, with a deficit per share of $-4.07. This is in stark contrast to the $-0.16 per share realized in the financial reporting period a year prior. In comparison to the prior financial reporting period, revenue decreased by -3.886% from $2.68 million and saw an increased deficit from $-0.25 per share.
The net deficit of $-5.182 million for the financial period ending March 31 2023 is larger than the $-2.036 million recorded a year ago. This is troubling for the company, and it must take steps to address the potential reasons for these financial losses, whether it relates to pricing strategies, operational efficiency or something else. The company is expected to report next financial results on May 18, 2023. This will give investors a better understanding of the company?s financial health.
In conclusion, the financial results of Thermogenesis Holdings Inc are concerning overall, and there is no doubt that the company needs to take corrective measures to improve its financial performance. Understanding the reasons behind these losses is essential to rectify the situation, and the company should communicate any steps it plans to take to its investors to restore confidence in its performance.

Accelerate Diagnostics Inc

Slight -4.936 %, revenue slide at AXDX during the most recent fiscal period

Accelerate Diagnostics Inc. (AXDX) has been performing dismally, as evidenced by its latest financial results for the first quarter of 2023. The company has been making significant losses, and its revenue has been declining, making it a risky investment option. The company's inability to generate profits and increase revenue raises concerns about its long-term viability, making it an unfavorable choice for investors.
For the first quarter of 2023, AXDX reported a loss of $-0.17 per share, compared to $-0.20 per share in the previous year. Despite this slight reduction, the company's loss grew from $-0.12 per share in the previous reporting season. This means that the company's financial performance is not improving, creating doubts about its ability to turn its fortunes around.

Phenomex Inc

revenue regressed, at the company during the January to March 31 2023 interval

Despite facing some challenging financial situations in the first quarter of 2023, Phenomex Inc continues to move forward with optimism and determination. The company's revenue may have decreased by 8.364%, but the good news is that Phenomex Inc was able to decrease its loss per share from $-0.40 to $-0.31 per share. This is a clear indication that the company is taking the necessary steps to turn things around and regain its footing.
It is important to note that Phenomex Inc is not alone in experiencing a decline in revenue and an increase in deficit. Many companies in the healthcare sector are facing similar challenges due to lower demand. However, what sets Phenomex Inc apart is their resilience and strategic approach to tackling these issues head-on.

Telesis Bio Inc

The Diminishing Returns have widen to $-0.37 at the Laboratory Analytical Instruments company during the most recent fiscal period

Telesis Bio Inc, a healthcare company, recently reported a return on average invested assets (ROI) of 5.61% in the first quarter of 2023, which is higher than its average ROI of 5.02%. However, the ROI decreased compared to the period ending December 31, 2022, due to the decline in net income.
The healthcare sector had 108 companies with a higher ROI than Telesis Bio Inc. The company's total ranking deteriorated to 1020 compared to the fourth quarter of 2022.



About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071